title: Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –.
abstract: BACKGROUND
  Little is known about the differences between standard-dose statins effects on glucose level and lipids in Japanese patients with diabetes mellitus (DM).
  
  
  RESULTS
  The 1,049 patients were randomly assigned to either the rosuvastatin group or atorvastatin group. There were no significant differences between the 2 groups in the effect on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c at 12 months. However, physicians tended to switch to more intensive therapy for DM in the atorvastatin group.
  
  
  CONCLUSIONS
  Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels.
authors.affiliation: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University.
authors.forename: Hisao
authors.initials: H
authors.lastname: Ogawa
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Matsui
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Saito
authors.forename: Seigo
authors.initials: S
authors.lastname: Sugiyama
authors.forename: Hideaki
authors.initials: H
authors.lastname: Jinnouchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sugawara
authors.forename: Izuru
authors.initials: I
authors.lastname: Masuda
authors.forename: Hisao
authors.initials: H
authors.lastname: Mori
authors.forename: Masako
authors.initials: M
authors.lastname: Waki
authors.forename: Minoru
authors.initials: M
authors.lastname: Yoshiyama
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Watada
mesh_terms: D044466:Asian People; D000069059:Atorvastatin; D001786:Blood Glucose / Q000378:metabolism*; D008076:Cholesterol, HDL / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D007564:Japan; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D000069059:Atorvastatin; D001786:Blood Glucose; D008076:Cholesterol, HDL; D005464:Fluorobenzenes; D006442:Glycated Hemoglobin; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides; C517652:hemoglobin A1c protein, human